Article ; Online: Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy.
2020 Volume 34, Issue 11, Page(s) 3088–3090
MeSH term(s) | Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/drug effects ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use ; Biomarkers, Tumor ; Humans ; Multiple Myeloma/blood ; Multiple Myeloma/diagnosis ; Multiple Myeloma/drug therapy ; Prognosis ; Signaling Lymphocytic Activation Molecule Family/blood ; Treatment Outcome |
---|---|
Chemical Substances | Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; Biomarkers, Tumor ; SLAMF7 protein, human ; Signaling Lymphocytic Activation Molecule Family ; elotuzumab (1351PE5UGS) |
Language | English |
Publishing date | 2020-05-12 |
Publishing country | England |
Document type | Letter ; Research Support, Non-U.S. Gov't |
ZDB-ID | 807030-1 |
ISSN | 1476-5551 ; 0887-6924 |
ISSN (online) | 1476-5551 |
ISSN | 0887-6924 |
DOI | 10.1038/s41375-020-0860-7 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 2295: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.